Quincy Lee
Ancient Art (Teton Capital)
Quincy Lee The Medicines Company stake
total: 149
Ancient Art (Teton Capital) MDCO trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2019 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2019 Q2
According to 2026 Q2 report, Quincy Lee doesn't hold any The Medicines Company (MDCO) shares. To date, the estimated cost basis is nearly $27.94 for "buy" trades and estimated average "sell" price is $27.94. Ancient Art (Teton Capital) first purchased MDCO in 2019 Q1, initially acquiring 27,520 shares. Since the initial investment in The Medicines Company (MDCO), Ancient Art (Teton Capital) has made 1 more transaction.
When did Quincy Lee sell The Medicines Company (MDCO)?
Quincy Lee sold off the entire The Medicines Company (MDCO) position in 2019 Q2.
When did Quincy Lee buy The Medicines Company (MDCO)?
Quincy Lee first invested in The Medicines Company (MDCO) in 2019 Q1 at the reported quarter-end price of $27.94 per share.
What's the cost basis of Ancient Art (Teton Capital)'s MDCO stake?
The estimated cost basis for The Medicines Company (MDCO) stake is around $27.94 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $27.94
- Weighted AVG sell price:
- $27.94
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.